Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Allogene Therapeutics (ALLO) announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor Biotechnologies to utilize the latter’s proprietary CRISPR gene-editing technology.Allogene intends to utilize Arbor’s CRISPR technology with its own proprietary platform to develop next-generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID).However, neither of the companies disclosed any specific financial terms or considerations pertaining to the abov ...